Travere Therapeutics (TVTX) Expected to Announce Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) is expected to announce its Q1 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect Travere Therapeutics to post earnings of ($0.54) per share and revenue of $77.44 million for the quarter.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $74.79 million during the quarter, compared to analysts' expectations of $72.38 million. On average, analysts expect Travere Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Travere Therapeutics Stock Down 1.1 %

NASDAQ TVTX traded down $0.24 during trading hours on Thursday, hitting $20.58. 660,152 shares of the company were exchanged, compared to its average volume of 1,516,211. The company has a 50 day moving average of $18.08 and a two-hundred day moving average of $18.69. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -5.02 and a beta of 0.84. Travere Therapeutics has a 52-week low of $5.54 and a 52-week high of $25.29.

Insider Activity

In related news, CEO Eric M. Dube sold 50,691 shares of Travere Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $20.21, for a total transaction of $1,024,465.11. Following the completion of the transaction, the chief executive officer now directly owns 430,548 shares in the company, valued at $8,701,375.08. The trade was a 10.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Sandra Calvin sold 54,244 shares of the business's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,410 shares of the company's stock, valued at approximately $1,360,250. This trade represents a 49.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 156,330 shares of company stock worth $3,507,377 over the last 90 days. 4.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on TVTX shares. Canaccord Genuity Group boosted their target price on shares of Travere Therapeutics from $45.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. JPMorgan Chase & Co. increased their price target on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Citigroup upped their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday, February 24th. Bank of America raised their price target on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Finally, Guggenheim reiterated a "buy" rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research note on Monday, April 14th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Travere Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $32.08.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.